Latest National Organization for Rare Disorders Stories
Advocacy groups warn that Senate version of bill would not eliminate caps for millions of Americans WASHINGTON, Jan.
WASHINGTON, Dec. 14 /PRNewswire-USNewswire/ -- The National Organization for Rare Disorders (NORD) today called upon Congress to put an immediate end to lifetime and annual health insurance caps.
CLAREMONT, Calif., Dec. 9 /PRNewswire/ -- The U.S.
DANBURY, Conn., Oct.
DANBURY, Conn., July 31 /PRNewswire-USNewswire/ -- The following letter regarding health care reform was sent to all members of Congress today by the National Organization for Rare Disorders (NORD): July 31, 2009 Dear Member of Congress: On behalf of the 30 million Americans who are affected by one of the nearly 7,000 rare disorders, we urge you to pass comprehensive health reform legislation designed to assure that every American, regardless of health status, has access to affordable,...
EXTON, Pa., May 18 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) was honored with a Corporate Award at the National Organization for Rare Disorders (NORD) Annual Gala for its work in bringing Cinryze(TM) (C1 esterase inhibitor (human)) to market for a rare and devastating disorder -- hereditary angioedema (HAE). HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein.
National Organization for Rare Disorders (NORD) Recognizes BioMarin's Efforts to Expand Treatment Options for Patients with PKU NOVATO, Calif., May 15 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc.
WASHINGTON, May 14 /PRNewswire-USNewswire/ -- A shortage of new pharmaceutical products in the pipeline combined with new scientific tools has created a climate of opportunity for the rare disease community, a senior Food and Drug Administration (FDA) official said today at a conference hosted by the National Organization for Rare Disorders (NORD). The blockbuster model is no longer viable, said Janet Woodcock, MD, director of the Center for Drug Evaluation and Research at FDA.
- A serpent whose bite was fabled to produce intense thirst.